"BPDCN 500 - 1000 cases in US annually, of which 60 -70% become relapsed/refactory so that puts that at 300-700 in US, seeking alpha wild guess was to double that for international markets. See slide 16"
My take on this is that they are going for all comers in BPDCN, not just the 60-70% R/R. That is why they are studying an additional 20 'Front line' patients that have not been previously treated. The market is just too small to treat only a subsegment of the population with this disorder. Remember, they are applying for FULL approval in BPDCN.
Someone correct me if I'm wrong.
